Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

BACKGROUND: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remains at approximately 14%, reflecting the lack of effectiveness of currently avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Susan A., Morrissey, Maria E., Dunne, Margaret R., O’Connell, Fiona, Butler, Clare T., Cathcart, Mary-Clare, Buckley, Amy M., Mehigan, Brian J., Larkin, John O., McCormick, Paul, Kennedy, Breandán N., O’Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532092/
https://www.ncbi.nlm.nih.gov/pubmed/33008336
http://dx.doi.org/10.1186/s12885-020-07430-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532092/
https://www.ncbi.nlm.nih.gov/pubmed/33008336
http://dx.doi.org/10.1186/s12885-020-07430-y

Ejemplares similares